Clinicopathologic Significance of Cathepsin B and Urokinase-type Plasminogen Activator Immunostaining in Colorectal Adenocarcinoma

Daniel W Visscher, B. Sloane, Wael Sakr, M. Sameni, D. Weaver, D. Bouwman, John D. Crissman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Acetone-fixed cryostat sections of 52 colorectal adenocarcinomas (26 stage B, 26 stage C) were immunostained with antibodies for two “invasion-associated” proteolytic enzymes—cathepsin B and urokinase-type plasminogen activator. Cathepsin B immu nostaining of neoplastic cells was observed in 21 tumors (40%). It was generally accompanied by staining among peritumoral host cells. There was no correlation be tween neoplastic cell cathepsin B staining and tumor stage (stage B, 42% positive vs stage C, 38% positive) however staining was more frequent in tumors that recurred (cathepsin B negative, 23% recurred vs cathepsin B positive, 48% recurred, P = .05-.06,25 months follow-up). Significant neoplastic cell urokinase-type plasminogen activator staining was present in only six cases (12%); however, peritumoral spindle and inflammatory cells exhibited positivity in 35% of tumors. There was no correlation between host cell derived urokinase-type plasminogen activator staining and either node metastasis or patient outcome. Tumors that stained for both neoplastic cell ca thepsin B and stromal cell urokinase-type plasminogen activator (12%) characterized a morphologically and clinically aggressive subset, compared to cases that stained for only one (51%) or neither (37%) enzyme (both positive, 83% recurred, 83% poorly differentiated vs neither positive, 26% recurred, 5% poorly differentiated). These data imply that invasion-associated proteases are derived from heterogeneous cellular sources in colorectal tumors. Further, synergistic protease activity may promote aggres sive clinical behavior accounting, in part, for the adverse prognostic significance of poor differentiation. Int J Surg Pathol 1(4):227-234, 1994

Original languageEnglish (US)
Pages (from-to)227-234
Number of pages8
JournalInternational Journal of Surgical Pathology
Volume1
Issue number4
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Cathepsin B
Urokinase-Type Plasminogen Activator
Adenocarcinoma
Staining and Labeling
Neoplasms
Peptide Hydrolases
Polysorbates
Stromal Cells
Acetone
Colorectal Neoplasms
B-Lymphocytes
Neoplasm Metastasis
Antibodies
Enzymes

Keywords

  • cathepsin B
  • colorectal adenocarcinoma
  • immu noperoxidase
  • plasminogen activator

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

Clinicopathologic Significance of Cathepsin B and Urokinase-type Plasminogen Activator Immunostaining in Colorectal Adenocarcinoma. / Visscher, Daniel W; Sloane, B.; Sakr, Wael; Sameni, M.; Weaver, D.; Bouwman, D.; Crissman, John D.

In: International Journal of Surgical Pathology, Vol. 1, No. 4, 1994, p. 227-234.

Research output: Contribution to journalArticle

Visscher, Daniel W ; Sloane, B. ; Sakr, Wael ; Sameni, M. ; Weaver, D. ; Bouwman, D. ; Crissman, John D. / Clinicopathologic Significance of Cathepsin B and Urokinase-type Plasminogen Activator Immunostaining in Colorectal Adenocarcinoma. In: International Journal of Surgical Pathology. 1994 ; Vol. 1, No. 4. pp. 227-234.
@article{0aeb91bd8e8b4a01bd1558772916a419,
title = "Clinicopathologic Significance of Cathepsin B and Urokinase-type Plasminogen Activator Immunostaining in Colorectal Adenocarcinoma",
abstract = "Acetone-fixed cryostat sections of 52 colorectal adenocarcinomas (26 stage B, 26 stage C) were immunostained with antibodies for two “invasion-associated” proteolytic enzymes—cathepsin B and urokinase-type plasminogen activator. Cathepsin B immu nostaining of neoplastic cells was observed in 21 tumors (40{\%}). It was generally accompanied by staining among peritumoral host cells. There was no correlation be tween neoplastic cell cathepsin B staining and tumor stage (stage B, 42{\%} positive vs stage C, 38{\%} positive) however staining was more frequent in tumors that recurred (cathepsin B negative, 23{\%} recurred vs cathepsin B positive, 48{\%} recurred, P = .05-.06,25 months follow-up). Significant neoplastic cell urokinase-type plasminogen activator staining was present in only six cases (12{\%}); however, peritumoral spindle and inflammatory cells exhibited positivity in 35{\%} of tumors. There was no correlation between host cell derived urokinase-type plasminogen activator staining and either node metastasis or patient outcome. Tumors that stained for both neoplastic cell ca thepsin B and stromal cell urokinase-type plasminogen activator (12{\%}) characterized a morphologically and clinically aggressive subset, compared to cases that stained for only one (51{\%}) or neither (37{\%}) enzyme (both positive, 83{\%} recurred, 83{\%} poorly differentiated vs neither positive, 26{\%} recurred, 5{\%} poorly differentiated). These data imply that invasion-associated proteases are derived from heterogeneous cellular sources in colorectal tumors. Further, synergistic protease activity may promote aggres sive clinical behavior accounting, in part, for the adverse prognostic significance of poor differentiation. Int J Surg Pathol 1(4):227-234, 1994",
keywords = "cathepsin B, colorectal adenocarcinoma, immu noperoxidase, plasminogen activator",
author = "Visscher, {Daniel W} and B. Sloane and Wael Sakr and M. Sameni and D. Weaver and D. Bouwman and Crissman, {John D.}",
year = "1994",
doi = "10.1177/106689699400100403",
language = "English (US)",
volume = "1",
pages = "227--234",
journal = "International Journal of Surgical Pathology",
issn = "1066-8969",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Clinicopathologic Significance of Cathepsin B and Urokinase-type Plasminogen Activator Immunostaining in Colorectal Adenocarcinoma

AU - Visscher, Daniel W

AU - Sloane, B.

AU - Sakr, Wael

AU - Sameni, M.

AU - Weaver, D.

AU - Bouwman, D.

AU - Crissman, John D.

PY - 1994

Y1 - 1994

N2 - Acetone-fixed cryostat sections of 52 colorectal adenocarcinomas (26 stage B, 26 stage C) were immunostained with antibodies for two “invasion-associated” proteolytic enzymes—cathepsin B and urokinase-type plasminogen activator. Cathepsin B immu nostaining of neoplastic cells was observed in 21 tumors (40%). It was generally accompanied by staining among peritumoral host cells. There was no correlation be tween neoplastic cell cathepsin B staining and tumor stage (stage B, 42% positive vs stage C, 38% positive) however staining was more frequent in tumors that recurred (cathepsin B negative, 23% recurred vs cathepsin B positive, 48% recurred, P = .05-.06,25 months follow-up). Significant neoplastic cell urokinase-type plasminogen activator staining was present in only six cases (12%); however, peritumoral spindle and inflammatory cells exhibited positivity in 35% of tumors. There was no correlation between host cell derived urokinase-type plasminogen activator staining and either node metastasis or patient outcome. Tumors that stained for both neoplastic cell ca thepsin B and stromal cell urokinase-type plasminogen activator (12%) characterized a morphologically and clinically aggressive subset, compared to cases that stained for only one (51%) or neither (37%) enzyme (both positive, 83% recurred, 83% poorly differentiated vs neither positive, 26% recurred, 5% poorly differentiated). These data imply that invasion-associated proteases are derived from heterogeneous cellular sources in colorectal tumors. Further, synergistic protease activity may promote aggres sive clinical behavior accounting, in part, for the adverse prognostic significance of poor differentiation. Int J Surg Pathol 1(4):227-234, 1994

AB - Acetone-fixed cryostat sections of 52 colorectal adenocarcinomas (26 stage B, 26 stage C) were immunostained with antibodies for two “invasion-associated” proteolytic enzymes—cathepsin B and urokinase-type plasminogen activator. Cathepsin B immu nostaining of neoplastic cells was observed in 21 tumors (40%). It was generally accompanied by staining among peritumoral host cells. There was no correlation be tween neoplastic cell cathepsin B staining and tumor stage (stage B, 42% positive vs stage C, 38% positive) however staining was more frequent in tumors that recurred (cathepsin B negative, 23% recurred vs cathepsin B positive, 48% recurred, P = .05-.06,25 months follow-up). Significant neoplastic cell urokinase-type plasminogen activator staining was present in only six cases (12%); however, peritumoral spindle and inflammatory cells exhibited positivity in 35% of tumors. There was no correlation between host cell derived urokinase-type plasminogen activator staining and either node metastasis or patient outcome. Tumors that stained for both neoplastic cell ca thepsin B and stromal cell urokinase-type plasminogen activator (12%) characterized a morphologically and clinically aggressive subset, compared to cases that stained for only one (51%) or neither (37%) enzyme (both positive, 83% recurred, 83% poorly differentiated vs neither positive, 26% recurred, 5% poorly differentiated). These data imply that invasion-associated proteases are derived from heterogeneous cellular sources in colorectal tumors. Further, synergistic protease activity may promote aggres sive clinical behavior accounting, in part, for the adverse prognostic significance of poor differentiation. Int J Surg Pathol 1(4):227-234, 1994

KW - cathepsin B

KW - colorectal adenocarcinoma

KW - immu noperoxidase

KW - plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=84973703216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973703216&partnerID=8YFLogxK

U2 - 10.1177/106689699400100403

DO - 10.1177/106689699400100403

M3 - Article

VL - 1

SP - 227

EP - 234

JO - International Journal of Surgical Pathology

JF - International Journal of Surgical Pathology

SN - 1066-8969

IS - 4

ER -